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The COVID-19 pandemic has worldwide individual and socioeconomic consequences. Chest computed tomography has been
found to support diagnostics and disease monitoring. A standardized approach to generate, collect, analyze, and share clinical and
imaging information in the highest quality possible is urgently needed. We developed systematic, computer-assisted and context-
guided electronic data capture on the FDA-approved mint LesionTM software platform to enable cloud-based data collection and
real-time analysis. The acquisition and annotation include radiological findings and radiomics performed directly on primary
imaging data together with information from the patient history and clinical data. As proof of concept, anonymized data of 283
patients with either suspected or confirmed SARS-CoV-2 infection from eight European medical centers were aggregated in data
analysis dashboards. Aggregated data were compared to key findings of landmark research literature. This concept has been
chosen for use in the national COVID-19 response of the radiological departments of all university hospitals in Germany.
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INTRODUCTION
Infection with the virus now known as SARS-CoV-2 has developed
into an ongoing pandemic, since the first cases in Hubei province,
China were reported to the WHO on December 31, 2019. This has
led to a global health crisis with substantial impact on both the
patients with COVID-19 at the individual level and on socio-
economic systems worldwide.
The high contagiousness of the disease, a substantial propor-
tion of asymptomatic cases and undocumented infections, and
dynamic movement patterns have combined to cause rapid
dissemination of the infection1–3. With cases globally still on the
rise and a lack of effective treatments or vaccines, the spread can
currently only be slowed down by drastic disease containment
efforts2–8. The pandemic has shown that existing measures for
disease control were inadequate and that even countries with a
strong healthcare infrastructure have insufficient critical care
resources. The current spread in low-income countries or those
with weak healthcare systems is posing challenges.
Along with the more effective containment, the most promising
approach to closing the gap in disease management is to broaden
the evidence base by expanding research into clinical diagnostics,
treatment, and disease monitoring, especially by taking advantage
of new technologies and artificial intelligence9,10. However, the
impact of aggregation and analysis on the individual patient and
on cohorts is high. The highest quality standards are therefore
mandatory, and can be attained only by using certified medical
software that complies with the regulations of the US Food and
Drug Administration (FDA) and the European Economic Area (CE
marking). The global spread of COVID-19 demands a global
response. Hope exists that aggregation of medical research data
and knowledge transfer between countries can substantially
expedite the understanding and management of COVID-19.
However, these efforts are currently hindered by a number of
factors. For one, standardized data reporting is often not available,
and, in many cases, common standards have not been defined
universally and conclusively. Research efforts like the CO-RADS11
or COVID-RADS12 standard that address these challenges need to
be integrated in a workflow system that can be disseminated
globally. The need for a global response means that standardized
datasets are needed for comparable results. Moreover, essential
diagnostic information is generally spread over several informa-
tion systems for data generation, storage, and reporting. Finally,
the definitions of most meaningful diagnostic tests and references
are still subject to frequent change, with a high volume of new
research findings. This means on the one hand that intensified
efforts toward evidence-based clinical diagnosis and treatment
along with reliable monitoring are essential. On the other hand, in
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order to achieve this in a short time, with comparable results and
broad scalability, reliable and efficient methods are needed. An
efficient electronic data capture (EDC) solution should therefore
support to dynamically be updated, reflecting newly discovered
relevant imaging findings as they are established in the course of
the pandemic. A combination of open access tried and secure
software environments, and state-of-the-art artificial intelligence
applications might provide suitable solutions9. However, these are
not currently readily available in the medical imaging domain.
Moreover, the wide range of requirements in the generation of
optimal evidence-based approaches and randomized controlled
trials necessitates a solution capable of aggregating, swiftly and
dynamically, the relevant excerpts from diagnostic, clinical, and
epidemiological datasets.
Therefore, we wish to initiate an open-access platform for the
data collection compliant with commonly developed criteria for
data formats and interfaces, using commonly developed criteria
for multimodal diagnosis, staging, and monitoring of COVID-19.
Therefore, a novel COVID-19 EDC that provides a direct linkage of
image and text annotation in a structured open data format for
joint international collaboration is developed. The proposed
platform represents the mandatory foundation for efficient, fast,
and dynamically adaptable conduct of clinical trials as a
prerequisite for novel evidence-based diagnostic and therapeutic
discoveries. To address these challenges, the radiology depart-
ments of all 36 university hospitals in Germany have combined to
set up the RACOON (Radiological Cooperative Network) initiative
for joint research into COVID-19 based on the software and cloud-
based data platform presented here.
RESULTS
Proof of concept: retrospective analysis of multicenter
template usage
In a class 2b/510k certified solution, we developed over a 3-week
period a context-sensitive electronic data capture (EDC) template
(Fig. 1) that enables systematic large-scale data acquisition to
provide an optimized digital platform to gather and aggregate
multidisciplinary scientific evidence on COVID-19. Our cloud-based
platform includes specific modules for acquisition, storage,
analysis, and automated reporting of healthcare data (Fig. 2).
The Mint EDC is used for an image-based, both manual and
automated data entry process to ensure comparability and
uniform data quality, and keep key missing values to a minimum.
In order to prove the feasibility of our concept, a retrospective
analysis of real-world evidence using the provided tool was
performed on data from seven European university hospitals and
one community healthcare center. We present the EDC-based
data acquisition and data analysis of the exemplary study
population, and compare the results to the key findings of three
landmark studies.
The study population comprised 283 inpatients and outpatients
from eight European medical centers, who received a clinically
indicated chest computed tomography (CT) examination and who
were either suspected or known (with laboratory confirmation) to
be infected with COVID-19. The selected medical centers provided
different levels of care. At each center, radiological assessment,
reporting, and data collection were performed independently of
this retrospective study. The completeness of the structured
reporting items was at the discretion of the examining radiologist.
The extracted data were visualized using a real-time statistics
dashboard integrated into the software and highly customizable
by the user (Fig. 3, for public dashboard access see “Data
availability” section). The aim of this usage analysis was to prove
the applicability of the concept for coherent multicenter data
acquisition by template-based reporting. Therefore, key research
literature was consulted to validate the eligibility of this approach.
A systematic review and meta-analysis of data pooled from
13 studies provided evidence on the radiological features of
pulmonary manifestations of COVID-19 in chest CT13. Normalized,
pooled data provided in the meta-analysis were used for
comparison with the data obtained with our COVID-19 template
submitted to real-time data analysis, displaying similar results
(Table 1). We found that in 76.0% of the rt-PCR-positive patients,
ground-glass opacity (GGO) lesions were detected at baseline
imaging. In the majority of the patients, more than one GGO
Fig. 1 COVID-19 EDC on the mint LesionTM software platform. In this example, the patient had confirmed COVID-19 and underwent chest
CT at two subsequent time points. The images were assessed and evaluated using the Mint EDC by an experienced radiologist. The
assessment and evaluation are performed directly on primary imaging data supported by the automatic rule-based evaluation of disease
progression. The patient was included in our feasibility clinical trial directly without the necessity for further data collection or redundant
documentation.
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lesion was documented at baseline imaging (five GGO lesions:
38.4%; four GGO lesions: 11.0%; three GGO lesions: 9.3%; and two
GGO lesions: 7.5%). The distribution of the parenchymal abnorm-
alities, including GGO lesions was found to be bilateral (overall
87.5%; rt-PCR positive 93.3%; and rt-PCR negative 32.5%),
peripheral (85.3; 87.3; and 76.6%), and affecting a minimum of
three lobes (58.9; 63.0; and 32.5%).
Besides the radiological findings, our cohort had clinical
presentations similar to those reported in the literature: 77.5%
of the rt-PCR-positive patients presented with fever (78.2% (ref. 14);
on admission 43.8% (ref. 15)/during hospitalization 88.7% (ref. 15))
and 74.6% with cough (62.4% (ref. 14) and 67.8% (ref. 15)). There
were discrepancies in the reporting of respiratory distress (overall
44.0%; rt-PCR positive 47.3%; and rt-PCR negative 34.1%;
compared with 1.0% reported with dyspnea by Zhao et al.14 and
18.7% reported with shortness of breath by Guan et al.15). The
discrepancy between the findings might be attributed to the time
point of examination in the course of disease, in which patients
that present at a later advanced stage show more severe
symptoms. In addition, respiratory distress, dyspnea, or shortness
of breath are often insufficiently defined in study protocols and
lack objective measures. Therefore, either the inclusion of
objective endpoints, such as oxygen saturation rate or exact
symptom definitions (here: in question complement) can con-
tribute to standardized data acquisition. At the time of first chest
CT examination, 173 patients had a confirmed SARS-CoV-2
infection by rt-PCR and 52 had been tested negative (chest CT
prior to rt-PCR test or clinical suspicion of COVID-19 despite rt-PCR
result). As part of the radiologist’s report, pulmonary findings were
assessed to be highly consistent with pulmonary manifestations of
COVID-19 in 146 cases (116 rt-PCR positive and 3 negative),
moderately consistent in 78 cases (39 rt-PCR positive and 24
negative), and not consistent in 37 cases (10 rt-PCR positive and
22 negative).
An approach for unified data collection and analysis using
comparable criteria
Our concept focuses on quality, integrity, and traceability. The
resulting data cloud provides the basis for the exploration of core
outcomes and hypothesis generation for future clinical trials. A
digital signature of COVID-19, consisting of imaging biomarkers,
patient history, and other clinical follow-up data obtained in a
reproducible manner, can be established with this method. The
structured data can be universally shared and analyzed, and may
be used for future studies on diagnostic support systems and risk
stratification by machine learning and artificial intelligence. We
demonstrated that a standardized EDC procedure can easily be
implemented globally by international dissemination of the
COVID-19 EDC for this retrospective analysis. Further, the EDC
enables international data contribution via the cloud-based
platform. Standardized assessment is possible only if the imaging
findings are collected and evaluated at a supra-regional,
preferably global level using comparable criteria. The Mint EDC
template is available free of charge for use in COVID-19 on the
mint LesionTM medical software product platform (Mint Medical,
Heidelberg, Germany; Figs. 1 and 2), and has already been used by
university hospitals and healthcare providers in eight countries,
including severely affected regions of the USA, Italy, Tyrol in
Austria, and the majority of the university hospitals in Germany as
a reporting solution in routine workflows, in research-focused
projects or a combination of either. The Mint EDC not only
provides a structured method for evaluating the pulmonary
involvement, but is also essential for quantitative assessment of
the progression of the disease, both in clinical trials and in daily
clinical routine. Besides providing a tool for clinical research, the
Mint EDC is integrated in routine patient assessment. We
demonstrate that structured data acquisition for clinical research
can be achieved within a structured reporting routine workflow at
a comparable time expenditure. In addition, automatic report
generation and dynamic adaptation of the Mint EDC to the latest
scientific evidence might facilitate this integration.
Furthermore, a cloud-based web platform was provided where
hospitals and healthcare centers can access the existing data and
upload, assess, report, and document their cases (Figs. 1 and 2). In
addition, this data platform enables working remotely and can
facilitate second opinions. All centers are encouraged to upload
their anonymized data to a central registry. The software features
an online dashboard that performs exploratory data analysis in
real time to monitor the patient’s progress and provide an alert if
applicable. In addition, users can customize the data analysis
dashboard. Here, we present a dashboard for exploratory analysis
Fig. 2 System architecture of a cloud-based web platform. Every healthcare center can upload anonymized data to the web platform and
use the Mint EDC based on the mint LesionTM medical product software package, either by using a local instance or directly via the cloud-
based web platform.
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that queries shared multicenter metadata that were acquired
using the COVID-19 Mint EDC (Fig. 3, for public dashboard access
see “Data availability” section). The provided tool also supports the
generation of single-center dashboards or dashboards for a
specific trial, which only query the same database. All data
records submitted to the cloud may be used to enhance the
knowledge of COVID-19 and contribute to improved clinical care
of COVID-19 patients in the near future.
Electronic data capture
A customizable EDC for COVID-19 that covers imaging data and
multidisciplinary medical data was developed. The Mint EDC
Fig. 3 Multicenter data aggregation in a real-time analytics dashboard. Overview of ad hoc COVID-19 usage analysis, including 283 patients
(upper left) from eight European hospitals. The data analysis dashboard is made publicly available on https://covid19.mint-imaging.com (for
details see “Data availability” section).
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template enables the data acquisition at different levels. In an EDC
procedure, recording of document-level patient data, such as
demographic information and exposure history, but also data
about diagnostic measures already performed and their results, is
requested of the user. In addition, secondary clinical data, such as
potentially relevant comorbidities, clinical symptoms, and clinical
chemistry are queried. The selection of parameters is based on the
current study evidence as described previously16. A dynamic flow
of refinements and amendments is possible with no risk of
diminishing the quality of previously collected data. Image
assessment includes general pulmonary radiological findings,
such as pleural effusion or lymphadenopathy. Pulmonary findings
that have been found to be compatible with COVID-19 or in
combination with other findings even indicative for COVID-19 are
automatically documented in a separate category depending on
the ensuing image findings. The EDC template allows for the
documentation and measurement of specific findings or general
longitudinal monitoring of primary data. Methodological
Table 1. Comparison of aggregated data from an ad hoc usage analysis using the COVID-19 template recommendation and proposed software
platform with key research findings.







Study population n= 2738 n= 1099 n= 101 n= 283a n= 173 n= 52





rt-PCR test negative 52 0 52
Mean age Median 47 (IQR 35.0–58.0) 44.4 ± 12.3 62 ± 15 61 ± 14 64 ± 17
Male (%) 1517 (55.4) 640 (58.2) 45 (44.6) 188 (66.4) 124 (71.7) 27 (51.9)
Female (%) 1221 (44.6) 459 (41.8) 56 (55.4) 95 (33.6) 49 (28.3) 25 (48.1)
CT imaging findings (%) (95% CI)
Ground-glass opacity 83.31
(69.43–93.35)
56.4 86.1 73.7 76.0 47.5
Consolidation 43.97
(32.82–55.45)












1.0 7.8 7.5 13.5
Lesion distribution (%) (95% CI)
Left 4.4 1.8 12.8
Right 8.1 4.9 21.3
Bilateral 78.2
(65.69–88.19)
82.2 87.5 93.3 66.0
Central 10.81
(0.12–41.50)
1.0 14.7 12.7 23.4
Peripheral 76.95
(57.43–91.50)
87.1 85.3 87.3 76.6
Lobes ≥ 3 70.81
(61.75–79.10)
58.9 (n= 224) 63.0 (n= 146) 32.5 (n= 40)
Clinical symptoms (%) b b b
Fever 43.8/88.7c 78.2 70.2 (n= 198) 77.5 (n= 142) 47.7 (n= 44)
Cough 67.8 62.4 71.9 (n= 199) 74.6 (n= 142) 69.6 (n= 46)
Sputum production 33.7 16.1 (n= 112) 14.3 (n= 84) 25.0 (n= 24)
Respiratory distress 18.7 1.0 44.0 (n= 200) 47.3 (n= 146) 34.1 (n= 44)
Nausea 5.0 2.0 9.4 (n= 171) 10.6 (n= 123) 7.5 (n= 40)
Headache 13.6 18.5 (n= 173) 21.4 (n= 126) 10.3 (n= 39)
Diarrhea 3.8 3.0 11.0 (n= 172) 11.4 (n= 123) 12.2 (n= 41)
All COVID-19 EDC data refer to the time of baseline imaging.
aIncluding all patients: rt-PCR positive, negative, not performed and unknown results of PCR test.
bReported data in structured reporting template by radiologist.
cOn admission/during hospitalization.
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consistency and conformity of the measurements are facilitated
by the software architecture, which has been described previously,
e.g., for RECIST 1.1 criteria17. As an example, once a user
documents a parenchymal lesion, he will be asked to specify the
location either by choosing from a graphical interface of the lung
anatomy or by selection from a prefiltered list of possible
locations, for all of which the unique identifier codes from
Radiology Lexicon (RadLex), Systemized Nomenclature of Medi-
cine (SNOMED), or NCI Thesaurus are additionally linked. In this
EDC, documentation of lesions in the category of parenchymal
lung abnormalities, which are not specified to be located within
the lung, will lead to an automatic indication of possible
irregularities in the conformity of the report. In order to approve
the report despite the noncompliance, the user will have to
manually justify their decision. Several of these conformity checks
have been implemented, in order to guarantee high quality of the
report and avoid errors of carelessness, thus ensuring the
acquisition of data with comparable quality across sites. Additional
automatically computed radiomics features provide secondary
data derived from the image that can be used for quantifying the
findings. Clinical researchers without programming knowledge
can extract radiomics features easily. The measurement of
parenchymal abnormalities and the documentation of the grade
of the lesion (e.g., ground-glass opacification) at each time point
(in the event of several examinations) is annotated to the lobular
sublocation in the lung. Bilateral lung involvement, the total
number of lung lobes involved, and other qualitative specifica-
tions of the lesions with regard to their sublocation are evaluated
automatically within a rule-based framework. This leads to an
intelligent and simplified workflow supported by logical con-
straints. A report for each time point and for the longitudinal
observation of the patient is generated automatically and can be
used for internal communication between departments (see
example in Fig. 4; for full report, see Supplementary Notes).
The particular strength of the Mint EDC lies in immediate
linkage of imaging-based values not only to the context, e.g.,
anatomical location, but also to further related data of clinical
significance—all in a structured way. Due to the integration in
the mint LesionTM software platform, mineable data are obtained
in a semantic data model with a HIPAA- and FDA CFR Part 11-
ready audit trail, immediately applicable for phases I–III clinical
trials and other medical research. Furthermore, the data are
exportable in various human- and machine-readable data
formats, such as comma-separated values (.csv) for external
analysis. All image annotations can be exchanged in open
formats, such as NRRD, or as DICOM-compliant annotations
(DICOM RT, DICOM Seg. Surface Obj.). Interfacing with other
information systems, such as hospital information systems (HIS)
to include clinical data, is possible through standardized
interfaces, including Health Level Seven, Fast Healthcare
Interoperability Resources (FHIR), and open electronic health
records. These interfaces can also be used to receive data and
transfer the automated report to the locally used radiological
information system, HIS, or other destinations.
DISCUSSION
The proposed solution supports the detection and standardized
recording of clinical and radiological disease features consistent
with the course of COVID-19 infection, as well as the relevant
epidemiological disease history. Furthermore, a predefined, readily
repeatable analysis workflow in the form of a customized analytics
dashboard can be used for swift extraction of relevant exploratory
statistics. Open access to aggregated anonymized data from this
study, usage of the data analysis dashboard, and download of
aggregated data is possible via https://covid19.mint-imaging.com,
as described in the “Data availability” section. We envisage that
this data-driven approach will be used in current and future
research into therapies and candidate vaccines for COVID-19, as
well as future virus pneumonias, fibrotic diffuse interstitial lung
diseases, or other diseases with complex characteristic patterns, as
the evaluation of clinical trials on novel therapies and the
development of risk stratification markers can be performed
using the provided Mint EDC template. In comparison with other
global data collection and analysis approaches, such as RICORD
(Radiological Society of North America) or the OpenSAFELY
platform18, the EDC template as one integral part of the presented
data collection, and analysis platform will ensure high-quality data,
but can also be used for immediate clinical assessment and
automatic report generation in clinical routine. In addition,
analysis on the provided real-time dashboard can be performed
on current, and ongoing data reported via this structured
approach due to the systematic and harmonized data collection.
As of today, many of the published studies lack a sufficient
number of cases or presented only retrospective results with
partially incomplete information due to challenges in data
acquisition. The ad hoc usage analysis presented herein is itself
restricted to an exploratory data analysis due to the relatively
small number of cases. Thus, we agree with the authors of other
studies that there is a need for larger trials with the systematic
data acquisition in the immediate future15,19.
We created the Mint EDC template based on current knowl-
edge. As radiologists become more familiar with the radiological
findings typical for COVID-19, the proposed EDC will contribute
substantially to the diagnosis and treatment of SARS-CoV-2
infection, and facilitate pooling of knowledge across national
boundaries. The template, together with its automatically
generated reports and computer assistance, might also serve as
a learning platform for further education. The rapid spread of
COVID-19 in the ongoing pandemic has shown that extensive
Fig. 4 Overview of locations of major findings on chest CT. Longitudinal overview of documented findings on chest CT examination (here:
evaluation after second chest CT in COVID-19 disease course). Decrease in the size (LA long axis, SA short axis) of the imaging findings. These
findings are included in an automatically generated case report file for a COVID-19-positive patient and study data repository.
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preparation and adjustment of healthcare systems is crucial, in
order to be able to respond appropriately and in timely manner.
We hope that the structured guidance through the radiological
assessment together with the pooled information gathered from
other sites might contribute to flatten the learning curve, and thus
improve clinical management of patients suffering from COVID-19.
Furthermore, resource scarcity in relation to the number of cases
has been widely experienced in terms of medical consumables
and infrastructure, but there has also been a shortage of
healthcare professionals. A cloud-based web platform obviates
the need for physical proximity to the hospitals or protection
measures for radiologists. Teleradiology services can readily be
enabled based on the proposed concept, thus leading to larger
capacities for COVID-19 and other applications.
Our approach has limitations. Data acquisition and handling are
more time consuming with an EDC template than a routine clinical
reading. Further, integral data acquisition of imaging and clinical
parameters requires interdisciplinary input, which might not be
available for every case. Template usage statistics have shown that
relevant information, e.g., clinical symptoms, that is not directly
available to the radiologist may be missed in documentation,
resulting in incomplete datasets. Incomplete or missing clinical
information is a known issue in radiological assessment that
impairs diagnostic accuracy20. Thus, the completeness and quality
of relevant clinical information are to be considered in radiological
reporting20. Therefore, “role-dependent” templates can be pro-
vided as solutions that integrate into one structured dataset. In
the future development of a “role-dependent” EDC, we aim to
define task templates that consist of subsets of data items to be
automatically assigned to the radiologist, but also to, e.g., other
clinicians or study nurses in order to improve workflow efficiency,
data quality, and use of human resources. In addition, conformity
and interdependence checks, rule-based automatic assistance and
automatic data capture, using the FHIR interface might contribute
to complete datasets and reduce processing time. Currently, the
template is designed for CT imaging only, but an EDC template for
chest radiographs could be realized easily and is planned for the
future. Further its use could aid in the systematic workup of
extrapulmonary imaging findings. Lastly, it might appear illogical
to encourage increased research even though manpower is
currently limited. The primary goal is to provide a tool for future
clinical studies, which are urgently needed.
We do not want to present a predefined global standard for the
assessment and reporting of patients with COVID-19; rather, our
intention is to initiate an evidence-based approach to define a
joint global standard that can be adapted to dynamic situations
and to discoveries yet to come. As an example, accumulating
evidence indicates a key role of pulmonary vascular pathologies in
COVID-19 that can be assessed in chest CT and contribute to
improved patient management12,21–23. New evidence will be
evaluated and integrated in future versions of the Mint EDC.
Standardized data acquisition and aggregation may also reveal
regional differences in the expression of the disease depending on
the respective case load and regional healthcare capacity leading
to a dynamic patient management. The Mint EDC can be adapted
and refined according to evidence generated in ongoing and
future clinical trials, and additional reporting items, e.g., the CO-
RADS11 or COVID-RADS12 assessment, can be added and
determined retrospectively. Any addition to or changes in
template parameters will not endanger previously collected data.
Permanent data integrity is assured, and even retrospective
acquisition of certain parameters will be possible if required.
Chest CT as a supporting tool for both diagnosis and treatment
monitoring has distinct benefits, such as short turnaround time,
wide availability of the necessary equipment, and the possibility of
assessing the stage of the disease, including response to
treatments. However, it must be emphasized that even though
the reporting is conducted directly on the CT image data, the EDC
template can be used even if no imaging dataset is available.
Parameters regarding the patient history, clinical symptoms, and
clinical chemistry could still be documented systematically and
shared with other ongoing activities, such as the LEOSS project24.
Consequently, the target group of users includes not only
radiological departments, but every other department that
contributes to the diagnosis and treatment of COVID-19 patients.
The presented platform will be used by all 36 German university
hospitals in the recently initiated joint nationwide infrastructure
initiative RACOON. The cloud-based platform is integral in the
development of a unified backbone for data annotation, analysis,
and exchange among the partners. With the presented systematic,
computer-assisted, and context-guided approach to data capture
and annotations based on easy-to-use software, we wish to
contribute to a joint global response against the COVID-19
pandemic in a balancing act between research and clinical routine
and, moreover, to initiate a change in clinical study culture.
METHODS
mint LesionTM software platform
The mint LesionTM platform provides radiologists, physicians, and
researchers with a certified medical product software for assessment of
radiological images. Users can examine and process these images, identify
structures and features, and perform measurements on them. Typical uses
are screening, staging, and treatment response monitoring in various types
of cancer. User guidance along a detailed workflow process is provided, in
which every clinical finding and measurement is tied to the respective
metadata. Data collection, annotation, and analysis were performed on a
dedicated and private cloud platform hosted in Germany. All data are
secured in a geo-redundant backup storage. State-of-the-art encryption for
all data in transit and at rest has been implemented by means of the
Advanced Encryption Standard-256 technology. Communication security
between servers and client web browsers is secured by Transport Layer
Security 1.2. Login credentials are personalized and follow a defined
password policy. The network storage is subdivided into an image buffer
that stores image data as imported via the provided upload/anonymiza-
tion tool without any changes on the actual images. Annotation, data
records etc. are stored in an open-source PostgresSQL database. An
independent and renown IT security company has performed an IT security
audit prior to the productive use. All observations of the audit have been
mitigated during the audit period. The auditors verified that no
observations were remaining unresolved.
Knowledge sources
In March 2020, we published the first version of the EDC using data items
based on a scientific literature review and the guidelines of the relevant
medical associations16,25,26. Due to the highly dynamic development of
knowledge about the pathophysiology, clinical presentation, and disease
course of COVID-19, continuous adjustments and amendments were
necessary for the data items queried in the COVID-19 Mint EDC. Updates of
the EDC template are performed based on continuous screening of the
scientific literature, and all refinements are validated by medical experts in
accordance with the predefined audit trail.
EDC template development
The template was developed based on the mint LesionTM software
platform allowing for implementation of customized reporting templates.
With a total of 67 reporting items, the template consists of document-level
data items that provide validity for each patient on a more general level,
accompanied by measurement-level data items in the context of a specific
annotation on the primary imaging data. Document-level data items
included the reporting categories “diagnostics” (rt-PCR test result and
antibody assay result), “demographic information”, “history of exposure to
infection”, “comorbidities”, “clinical symptoms”, “clinical chemistry”, “gen-
eral pulmonary radiological findings”, and “COVID-19 compatible radi-
ological findings”. The document-level questions mostly offer a choice of
three answers (yes/no/not evaluable), but have been customized where
applicable and offer free-text fields where appropriate. On the measure-
ment level, lesions can be documented using a range of annotation tools,
including simple maximum diameter or long axis/short axis measurements,
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but also free-form 2D or 3D segmentation by definition of the region of
interest to compute radiomics parameters. Each measurement is
documented on the primary image, including its specific anatomical
location. Rule-based automatic evaluations and automatic acquisition of
data items are implemented where applicable. As an example, the
laterality of lung manifestations (left/right/bilateral) and the number of
lung lobes involved are automatically derived from the documentation of
lesions on the primary imaging data based on their specified location.
Conformity checks specific to the COVID-19 reporting template are
included to ensure valid documentation of lesions. Wherever applicable,
further explanation or literature citations are provided for the queried
data items.
Implementation and dissemination
In March 2020, Mint Medical GmbH, Heidelberg, Germany deployed the
COVID-19 Mint EDC at all customer sites per configuration. The COVID-19
EDC template was installed free of charge, and there were no fees for its
use. For medical centers that did not already have a local Mint server
installed, a cloud-based software platform with secure remote access
options was developed and provided free of charge.
Template-based image assessment
Images were assessed by experienced radiologists at the participating
study centers. The radiological departments of the university hospitals of
Heidelberg (represented by Dept. of Radiology, Heidelberg University and
Dept. of Radiology, Thorax Clinic at Heidelberg University), Tuebingen,
Frankfurt, Innsbruck, Cologne, and Berlin, the Institut Jules Bordet in
Brussels, and the regional hospital of Heilbronn participated in this study.
There was no training in the use of structured reporting templates for
patient assessments in general or of the COVID-19 Mint EDC template in
particular, apart from the complimentary template description and user
manual provided.
Usage analysis: overview
The analysis was designed by the investigators. Ethical approval for
analysis of the de-anonymized metadata was obtained from the
appropriate review board by the coordinating study center at Heidelberg
University Hospital. Written informed consent was waived owing to the
retrospective usage of anonymized metadata. Anonymized data were
aggregated and visualized for descriptive analysis.
Usage analysis: definition and outcome
The primary intention was to prove the feasibility of using the COVID-19
EDC template for patient assessment, and subsequent systematic and
standardized data acquisition applicable for epidemiological and clinical
research by retrospective analysis of metadata. Therefore, landmark
research literature was used for comparison with the results of this
unsupervised, ad hoc, investigator-initiated, multicenter metadata analysis.
Data sources
Usage records of the developed COVID-19 EDC were obtained from all
participating study centers. All anonymized metadata were pooled for a
central analysis at the provided cloud server. Anonymization was
performed in a two-step process via an upload tool. First, all directly
identifying attributes were removed consistent with Attribute Confidenti-
ality profile (DICOM PS 3.15: Appendix E), according to DICOM Standard
committee (working group 18) Supplement 142. In a second step, the
patient ID is manipulated by multiple hashing using a cryptographic
method. Confidential information, partially deducted from patient data,
partially specific to the user is inserted as salt. The procedure is
nonreversible to all participants. However, longitudinal study data will still
be assigned correctly. Therefore, at least the level of qualified anonymiza-
tion as introduced by the Horizon 2020 DS-08-2017 “Cybersecurity PPP:
Privacy, Data Protection, Digital Identities” is fulfilled. The inclusion criteria
were either laboratory-confirmed or suspected COVID-19 infection and the
clinical indication for chest CT in a patient, who was either hospitalized or
being treated as an outpatient. Whether continuous cases were selected
and whether data were annotated with the EDC was purposely left to the
discretion of each participating site.
Dashboard data aggregation and statistical analysis
The data aggregation and analysis were performed using the software add-on
mint AnalyticsTM, which provided the possibility to perform real-time analysis,
using a configurable search engine and front end for visualization. The
software is open source based on a front-end application (Kibana) for queries
and visualization of data indexed in elasticsearch (Elasticsearch, Inc., US, elastic.
co). Numerical values were summarized as averages and standard deviations.
Categorical variables were expressed as percentages. No imputation was made
for missing data. The laterality of the lesions and the number of lobes affected
by pathological findings compatible with COVID-19 was derived automatically,
using a rule-based framework depending on the number of lesions annotated
and their respective locations within the lung. The cohort of patients assessed
with this COVID-19 EDC has not been randomized, and decisions on the
applicability of EDC template assessment and subsequent inclusion in this
analysis were at the discretion of the responsible medical centers; thus,
statistics are descriptive only. Baseline imaging time points were chosen for
analysis. Subgroup analyses were performed depending on the rt-PCR status
reported for each patient and divided into rt-PCR positive, rt-PCR negative, and
patients with either unknown rt-PCR status or no test performed.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The COVID-19 Mint EDC is demonstrated at http://cloud1.mint-medical.de/
downloads/player/index.html?v=Covid19StandardizedAssessmentWeb. Raw data
generated with the COVID-19 EDC used for this multicenter analysis remain the
property of the respective participating institution. The anonymized datasets of this
multicenter usage analysis were aggregated solely for the proof of concept of the
proposed data generation and analysis platform. We provide public access to the
data analysis dashboard and aggregated anonymized data on https://covid19.mint-
imaging.com (User-ID: mint, password: FightCovid!). Every reader has the opportunity
to use the dashboard and visualizations, filter for specific data, and download the
respective data. The presented data form part of several other medical research
projects and investigator-initiated trials and will be included in individual and joint
publications. For the German RACOON project, a committee for data access and
collaboration will be formed and can be reached via the corresponding author.
CODE AVAILABILITY
No nonproprietary, customized code was used for data analysis. The data analysis
dashboard and its framework can be accessed through https://covid19.mint-imaging.
com (User-ID: mint, password: FightCovid!).
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